Mortality results from a randomized prostate-cancer screening trial - Wikidata - wikimedia - TriplyDB

Mortality results from a randomized prostate-cancer screening trial

Mortality results from a randomized prostate-cancer screening trial

http://www.wikidata.org/entity/Q24601536

about

Body-Mass Index and Mortality among 1.46 Million White Adults Early assessment of cancer outcomes in New York City firefighters after the 9/11 attacks: an observational cohort study Screening for Prostate Cancer: Shaping the Debate on Benefits and Harms Screening for prostate cancer Antibiotic prophylaxis for transrectal prostate biopsy Lycopene for the prevention of prostate cancer Radical prostatectomy versus watchful waiting for prostate cancer Lycopene for the prevention of prostate cancer Screening for prostate cancer Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 RETRACTED: XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements Update on age-appropriate preventive measures and screening for Canadian primary care providers Current status of active surveillance in prostate cancer Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer Prostate Cancer for the Internist Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis Treatment options for localized prostate cancer Population screening for prostate cancer: an overview of available studies and meta-analysis The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis Multiparametric magnetic resonance imaging of the prostate: current concepts Kallikreins as biomarkers for prostate cancer Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles Management of low (favourable)-risk prostate cancer Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research Urinary biomarkers for prostate cancer Androgens and prostate disease Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes The genetics of cancer risk Emerging critical role of molecular testing in diagnostic genitourinary pathology A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential Prostate cancer: ESMO Consensus Conference Guidelines 2012 Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening

P2860

Q22250878-9EC43543-ADCF-4A8D-9980-BD7612AD76D4 Q24170267-44B3DD6B-B049-4323-B05C-5CEAC4BB059F Q24197953-0C3B9EE7-8C54-4B64-8C93-FD273B0DFC7A Q24201690-1A8699D7-2A0A-4240-A11F-467346C4B0AF Q24234567-E1D98ACD-F202-4768-99FF-6D0073A6DBDD Q24235388-4533E662-591D-4A72-8A4C-FE9F6F82644E Q24236564-EF779105-E11B-48B5-B88C-89E771AA05F6 Q24241585-A25D137C-E666-4DB4-B5CF-DA0D954FB519 Q24245476-0CFA1A34-3538-449A-A4F4-3C7323BECB27 Q24608493-36123034-9BD3-4005-B4F3-A3AD45BFBE7B Q24620320-49695C3E-05D2-48C2-A8AB-590273805937 Q24656098-6A360DB8-50B3-4929-8DAE-D4C19AEDE3A8 Q24658112-9E128237-0B11-4F7C-BD0F-987AE7F1AB07 Q26748873-0D35C52F-0F4A-43AC-9E42-6ED8855DA064 Q26750672-01C7FC02-FAB4-4A8D-B41F-688E611E4CA8 Q26765382-3EBE9146-921F-432E-A5CF-BE3A9BCBE245 Q26766307-C698CB70-1F82-4A79-A0DE-FD18730456E7 Q26767044-B667CBF9-4AB1-49EB-9782-C55A507605B5 Q26771721-7EB7AC5A-E097-4299-A345-4F84CEFF7997 Q26775766-C8E7AFDE-E418-4BC2-9109-B8E73EA02A65 Q26781093-520BDA58-882B-469D-BE7C-CEE276BA0B2B Q26825653-C298C1A9-DEF9-4D17-99C8-231CB0D76B56 Q26829319-412E7715-39BA-4315-9427-A0BD319917CC Q26858924-92AA7F85-3324-4C28-81F5-25F0669ADB92 Q26859699-E20385C0-B558-47ED-A7CB-F399D0DCA28F Q26862434-153B8110-689E-49C5-A6F3-EDF3B3192E59 Q26864419-64C5274E-34A3-4631-B968-598C53768877 Q26865810-22B09A07-B24E-4652-A8E5-10ADCD798D4E Q26996501-34C051C7-9FDB-45C3-9DB8-14CF6BEFF0E3 Q27001043-CE30D9B3-42F6-49E3-9025-99FE981287AC Q27001399-6F4ACB7A-2264-480A-9EF7-7DF3E2DA9477 Q27004458-72B66D34-8AC1-46D7-98F4-144A0581D551 Q27009110-2C876F19-6937-4DBE-A655-2DA71515F4F9 Q27010093-F9D91347-A195-44A0-9353-3E54E1F420A2 Q27010695-04AF88B4-1334-4213-B7F8-58028913AC32 Q27013910-15C98270-2978-4F5E-A0D3-7370A8B692B7 Q27021371-5B36C5BD-346A-441A-B95A-E294E4D62E64 Q27022638-F48D25DF-17AA-4161-89AF-27B774B16B29 Q27022847-A8F77185-6D1E-4FEC-B31A-3950C89DB3DA Q27025805-2B9859D3-A5CD-46EF-885A-AD5BD645C1E1

P2860

Mortality results from a randomized prostate-cancer screening trial

http://www.wikidata.org/entity/Q24601536

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Mortality results from a randomized prostate-cancer screening trial

@ast

Mortality results from a randomized prostate-cancer screening trial

@en

Mortality results from a randomized prostate-cancer screening trial

@nl

type

label

Mortality results from a randomized prostate-cancer screening trial

@ast

Mortality results from a randomized prostate-cancer screening trial

@en

Mortality results from a randomized prostate-cancer screening trial

@nl

prefLabel

Mortality results from a randomized prostate-cancer screening trial

@ast

Mortality results from a randomized prostate-cancer screening trial

@en

Mortality results from a randomized prostate-cancer screening trial

@nl

P1433

Q24601536-61ECCB7D-BCAA-4BD5-A1F9-7283BACFFDF3

P1476

Q24601536-E7D5CE4C-5E94-452D-8078-3390294B63AD

P2093

Q24601536-25A6724D-5F0D-44B5-8710-7913636BD6A3

Q24601536-3A2335CD-3823-48A0-9969-BEB45F2D5CCB

Q24601536-49CEFE70-0BE3-4C03-A661-CBCF32FE2667

Q24601536-4FB993E1-4F37-4B25-B3A2-F21FE86210A8

Q24601536-5298BA75-CBC6-453A-A103-36B4D8DAE972

Q24601536-5588152B-C954-4202-811B-132848B2D378

Q24601536-63366B61-760B-4DB5-8463-F03FE57F4454

Q24601536-676370F8-DE1C-46ED-9BAA-B3C11FFD58AB

Q24601536-7090D16F-CF45-4C32-90E6-392F7AB55029

Q24601536-70DAB6C3-54E3-4EAD-B626-F45B1059518F

P2860

Q24601536-00B51E20-3B6D-4EB2-AA01-030A56FB50DC

Q24601536-0C0946D2-DB81-4FA3-A118-5CBE82B90BFD

Q24601536-25A0282B-B046-4040-88A0-9135914C1CF0

Q24601536-2EE867D7-7C7A-4DA9-BEF8-0A2170D304E1

Q24601536-39416D33-EC64-4413-BE81-3FEF9654B370

Q24601536-4EA66931-A83E-43D1-9EFF-6B386F740536

Q24601536-614EFC06-ACFF-4CB9-86F2-72D6DD495DD9

Q24601536-6211A455-B952-4428-9334-196F98023BF0

Q24601536-69921413-D98B-4229-BE8D-C4193904B58F

Q24601536-70F5A2D0-E1AA-4BF9-8BF8-BD25898A658C

P304

Q24601536-49B674EF-74F8-4366-AA88-6FAC118BC965

P31

Q24601536-AC0383AE-8A6B-485D-A77A-A45FBFDA906E

P3181

Q24601536-093BAA12-ECA4-4309-9CAA-53D71862BEBA

P356

Q24601536-8C1C3272-9F08-42AA-B761-E6DCC4AAEDC1

P407

Q24601536-231CD87A-E7EE-482F-A6C4-93D473F7AB88

P433

Q24601536-D16A5897-9420-411D-8383-DB9E3D3D00C1

P478

Q24601536-361EC074-28D3-4B78-AECE-B100DC758B00

P50

Q24601536-9D99999F-8B2F-441E-9755-0DD028A27486

Q24601536-F7781F18-7A58-4CEA-9346-81A3DA42281E

P577

Q24601536-955034C7-E951-4965-970D-A2ED34C24801

P698

Q24601536-0BFD9B7D-F14E-4C72-8D59-C8A031420B6D

P932

Q24601536-F826061A-B44A-40C1-9A2C-E06C03D7B271

P3181

P356

P1433

The New England Journal of Medicine

P1476

Mortality results from a randomized prostate-cancer screening trial

@en

P2093

Anthony B Miller

http://www.w3.org/2001/XMLSchema#string

Barbara O'Brien

http://www.w3.org/2001/XMLSchema#string

Barnett S Kramer

http://www.w3.org/2001/XMLSchema#string

Christine D Berg

http://www.w3.org/2001/XMLSchema#string

David Chia

http://www.w3.org/2001/XMLSchema#string

Douglas J Reding

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Edward P Gelmann

http://www.w3.org/2001/XMLSchema#string

Gerald L Andriole

http://www.w3.org/2001/XMLSchema#string

Grant Izmirlian

http://www.w3.org/2001/XMLSchema#string

P2860

Screening and prostate-cancer mortality in a randomized European study

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

The role of increasing detection in the rising incidence of prostate cancer.

Radical prostatectomy versus watchful waiting in early prostate cancer.

The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma.

20-year outcomes following conservative management of clinically localized prostate cancer.

Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program.

P304

1310-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1735220

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0810696

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

360

http://www.w3.org/2001/XMLSchema#string

P50

Timothy R. Church

P577

2009-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19297565

http://www.w3.org/2001/XMLSchema#string

P932

2944770

http://www.w3.org/2001/XMLSchema#string